Temozolomide overcoming resistance to immune checkpoint inhibitors in relapsed/refractory metastatic melanoma? Insights from a single center series.

Autor: Dasanu CA; Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.; Department of Medical Oncology, UC San Diego Health System, San Diego, CA, USA., Plaxe SC; Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.; Department of Medical Oncology, UC San Diego Health System, San Diego, CA, USA.

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Nov 25, pp. 10781552241302421. Date of Electronic Publication: 2024 Nov 25.

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.

Autor: Goff CB; Department of Internal Medicine, Eisenhower Health, Rancho Mirage, CA, USA., Plaxe SC; Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.; Department of Medical Oncology and Hematology, University of California in San Diego Health System, San Diego, CA, USA., White W; Department of Internal Medicine, Eisenhower Health, Rancho Mirage, CA, USA., Dasanu CA; Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA, USA.; Department of Medical Oncology and Hematology, University of California in San Diego Health System, San Diego, CA, USA.

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Jul; Vol. 29 (5), pp. 1259-1263. Date of Electronic Publication: 2023 Feb 03.

Kappa light chain restriction correlates with peripheral neuropathy in patients with non-IgM monoclonal gammopathy of undetermined significance.

Autor: Dasanu CA; Eisenhower Lucy Curci Cancer Center, Rancho Mirage, California, USA.; University of California San Diego Health, San Diego, California, USA., Kaur J; Department of Medicine, Eisenhower Health, Rancho Mirage, California, USA., Farrell S; Eisenhower Lucy Curci Cancer Center, Rancho Mirage, California, USA., Plaxe SC; Eisenhower Lucy Curci Cancer Center, Rancho Mirage, California, USA.; University of California San Diego Health, San Diego, California, USA.

Publikováno v: European journal of haematology [Eur J Haematol] 2022 Jan; Vol. 108 (1), pp. 86-87. Date of Electronic Publication: 2021 Nov 03.

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.

Autor: Moore KN; Sarah Cannon Research Institute, Nashville, Tennessee. Kathleen-Moore@ouhsc.edu.; Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, Oklahoma., Chambers SK; The University of Arizona Cancer Center, Tucson, Arizona., Hamilton EP; Sarah Cannon Research Institute, Nashville, Tennessee.; Tennessee Oncology, PLLC, Nashville, Tennessee., Chen LM; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Oza AM; Bras Drug Development Program, Princess Margaret Cancer Centre, Toronto, Canada., Ghamande SA; Augusta University, Augusta, Georgia., Konecny GE; UCLA, Los Angeles, California., Plaxe SC; UC San Diego Health, La Jolla, California., Spitz DL; Sarah Cannon Research Institute, Nashville, Tennessee.; Florida Cancer Specialists & Research Institute, Wellington, Florida., Geenen JJJ; Netherlands Cancer Institute, Amsterdam, the Netherlands., Troso-Sandoval TA; Memorial Sloan Kettering Cancer Center, New York, New York., Cragun JM; The University of Arizona Cancer Center, Tucson, Arizona., Rodrigo Imedio E; Oncology Global Medicines Development (GMD), AstraZeneca, Cambridge, United Kingdom., Kumar S; Oncology Global Medicines Development (GMD), AstraZeneca, Cambridge, United Kingdom., Mugundu GM; Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts., Lai Z; Translational Medicine, Oncology Research and Development, AstraZeneca, Boston, Massachusetts., Chmielecki J; Translational Medicine, Oncology Research and Development, AstraZeneca, Boston, Massachusetts., Jones SF; Sarah Cannon Research Institute, Nashville, Tennessee., Spigel DR; Sarah Cannon Research Institute, Nashville, Tennessee.; Tennessee Oncology, PLLC, Nashville, Tennessee., Cadoo KA; Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jan 01; Vol. 28 (1), pp. 36-44. Date of Electronic Publication: 2021 Oct 13.

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.

Autor: Kato S; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA. smkato@ucsd.edu., Kim KH; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA. floresta405@gmail.com.; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea. floresta405@gmail.com., Lim HJ; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA.; Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea., Boichard A; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Nikanjam M; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Weihe E; Department of Radiology, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Kuo DJ; Division of Pediatric Hematology-Oncology, Rady Children's Hospital-San Diego, University of California San Diego School of Medicine, San Diego, CA, USA., Eskander RN; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Goodman A; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Galanina N; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Fanta PT; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Schwab RB; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Shatsky R; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Plaxe SC; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Sharabi A; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA.; Department of Radiation Medicine and Applied Sciences, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Stites E; Integrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, USA., Adashek JJ; Department of Internal Medicine, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Okamura R; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Lee S; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Lippman SM; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Sicklick JK; Center for Personalized Cancer Therapy and Division of Surgical Oncology, Department of Surgery, UC San Diego Moores Cancer Center, La Jolla, CA, USA., Kurzrock R; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA.

Publikováno v: Nature communications [Nat Commun] 2020 Oct 02; Vol. 11 (1), pp. 4965. Date of Electronic Publication: 2020 Oct 02.